StockNews.com assumed coverage on shares of NanoViricides (NYSE:NNVC – Free Report) in a report published on Wednesday morning. The brokerage issued a sell rating on the stock.
NanoViricides Price Performance
NNVC opened at $1.13 on Wednesday. The firm has a market capitalization of $13.31 million, a PE ratio of -1.40 and a beta of 0.70. The business’s 50-day moving average is $1.20 and its two-hundred day moving average is $1.16. NanoViricides has a 1 year low of $1.00 and a 1 year high of $2.00.
NanoViricides (NYSE:NNVC – Get Free Report) last released its quarterly earnings results on Wednesday, February 14th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.01.
NanoViricides Company Profile
NanoViricides, Inc, a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases.
Read More
- Five stocks we like better than NanoViricides
- Investing in Travel Stocks Benefits
- MarketBeat Week in Review – 4/29 – 5/3
- How to Invest in Biotech Stocks
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for NanoViricides Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoViricides and related companies with MarketBeat.com's FREE daily email newsletter.
